Loading...
Loading...
Analysts at Standpoint Research initiated coverage on Coherus Biosciences Inc CHRS with a Speculative Buy rating. The price target for Coherus Biosciences is set to $40. Coherus Biosciences shares closed at $28.10 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
